TITLE

Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease

AUTHOR(S)
Rigoli, Luciana; Romano, Claudio; Caruso, Rosario Alberto; Lo Presti, Maria A.; Di Bella, Chiara; Procopio, Vincenzo; Lo Giudice, Giuseppina; Amorini, Maria; Costantino, Giuseppe; Sergi, Maria D.; Cuppari, Caterina; Calabrò, Giovanna Elisa; Gallizzi, Romina; Salpietro, Carmelo Damiano; Fries, Walter; De Boer, Nanne K. H.; Kouroumalis, Elias A.
PUB. DATE
July 2008
SOURCE
World Journal of Gastroenterology;7/28/2008, Vol. 14 Issue 28, p4454
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
AIM: To evaluate the role of genetic factors in the pathogenesis of Crohn's disease (CD) and ulcerative colitis (UC), we investigated the single nucleotide polymorphisms (SNPs) of NOD2/CARD15 (R702W, G908R and L1007finsC), and Toll-like receptor 4 (TLR4) genes (D299G and T399I) in a selected inflammatory bowel disease (IBD) population coming from Southern Italy. METHODS: Allele and genotype frequencies of NOD2/CARD15 (R702W, G908R and L1007finsC) and TLR4 (D299G and T399I) SNPs were examined in 133 CD patients, in 45 UC patients, and in 103 healthy controls. A genotype-phenotype correlation was performed. RESULTS: NOD2/CARD15 R702W mutation was significantly more frequent in CD (9.8%) than in controls (2.4%, P = 0.001) and in UC (2.3%, P = 0.03). No significant difference was found between UC patients and control group (P > 0.05). In CD and UC patients, no significant association with G908R variant was found. L1007finsC SNP showed an association with CD (9.8%) compared with controls (2.9%, P = 0.002) and UC patients (2.3%, P = 0.01). Moreover, in CD patients, G908R and L1007finsC mutations were significantly associated with different phenotypes compared to CD wild-type patients. No association of IBD with the TLR4 SNPs was found in either cohort (allele frequencies: D299G-controls 3.9%, CD 3.7%, UC 3.4%, P > 0.05; T399I-controls 2.9%, CD 3.0%, UC 3.4%, P > 0.05). CONCLUSION: These findings confirm that, in our IBD patients selected from Southern Italy, the NOD2/CARD15, but not TLR4 SNPs, are associated with increased risk of CD.
ACCESSION #
35751481

 

Related Articles

  • Glucocorticoid Receptor Gene Polymorphisms and Glucocorticoid Resistance in Inflammatory Bowel Disease: A Meta-Analysis. Chen, Hong-Lin; Li, Li-Ren // Digestive Diseases & Sciences;Dec2012, Vol. 57 Issue 12, p3065 

    Background: Studies investigating the associations between glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease report conflicting results. Aims: We conducted a meta-analysis to assess the possible association between the three most commonly...

  • What Is Inflammatory Bowel Disease.  // Pediatrics for Parents;2001, Vol. 19 Issue 7, p3 

    Describes the inflammatory bowel disease (IBD). Role of Crohn's disease and ulcerative colitis on IBD; Distinction between the diseases of IBC; Treatments for IBD.

  • Assessing Response and Loss of Response to Biological Therapies in IBD. Yanai, Henit; Hanauer, Stephen B. // American Journal of Gastroenterology;Apr2011, Vol. 106 Issue 4, p685 

    OBJECTIVES:The advent of biological therapies for inflammatory bowel disease (IBD) began in 1998 with the approval of infliximab for the treatment of refractory (to conventional agents) Crohn's disease (CD). Since then, the indications for anti-tumor necrosis factor-α (anti-TNFα) therapy...

  • Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner? Fiorino, Gionata; Rovida, Serena; Correale, Carmen; Malesci, Alberto; Danese, Silvio // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p249 

    Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of Crohn's disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms trigger an event, leading to the...

  • Biologies can treat some cases of inflammatory bowel disease. Zablocki, Elaine // Managed Healthcare Executive;Dec2009, Vol. 19 Issue 12, p25 

    The article discusses the inflammatory bowel disease (IBD) in the U.S. in which the intestines become inflamed as a result of immune reaction mobilized against intestinal tissue. It notes that ulcerative colitis affects the rectum and colon while Crohn's disease affects the gastrointestinal...

  • Single-Port Laparoscopic Surgery for Inflammatory Bowel Disease. Rijcken, Emile; Mennigen, Rudolf; Senninger, Norbert; Bruewer, Matthias // Minimally Invasive Surgery (20901445);2012, p1 

    Background. Single Port Laparoscopic Surgery (SPLS) is being increasingly employed in colorectal surgery for benign and malignant diseases. The particular role for SPLS in inflammatory bowel disease (IBD) has not been determined yet. In this review article we summarize technical aspects and...

  • Microbial Links to Inflammatory Bowel Disease Development: Potential Interventional Strategies in Treatment. Singh, Udai P.; Singh, Narendra P.; Busbee, Brandon; Guan, H.; Price, Robert L.; Taub, Dennis D.; Mishra, Manoj K.; Nagarkatti, Mitzi; Nagarkatti, Prakash S. // Journal of Bacteriology & Parasitology;2012, Vol. 3 Issue 7, p1 

    The authors reflect on the results of several studies which found an increase in lactobacillus and bifidobacterium after treatment with resveratrol for Crohn's disease and ulcerative colitis. They state that the main mechanisms of inflammatory bowel disease are unknown, however studies revealed...

  • Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease - a population-based study.  // Inflammatory Bowel Disease Monitor;2012, Vol. 12 Issue 3, p128 

    The article reports on the study that identifies the phenotypic, treatment, and disease course differences betwen adult and pediatric inflammatory bowel disease (IBD) populations. It found no difference in Crohn's disease localization between pediatric and adult-onset patients. It reveals that...

  • Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p78 

    This excellent review summarizes the current challenges in IBD clinical trials and gives a rational series of recommendations for improvements.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics